FOLH1 and prostate cancer: Research by Weber et al. found that a polyvalent vaccine targeting PRAME and prostate-specific membrane antigen induced expansion of CD8+ T-cells recognizing PRAME and PSMA in 15 out of 24 prostate cancer patients.